Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada

Inclusion Criteria: * Participants able to give voluntary informed consent before starting any study-related assessments or procedures (to be obtained/documented as per local regulations). * Adults (≥18 years of age) at time of informed consent. * Participants with at least 1-year history of migraine with or without aura consistent with a diagnosis according to the ICHD-3 (2018). * Participants with history of experiencing at least 3 migraine attacks per month with moderate to severe symptoms * Participants prescribed ubrogepant by investigator for the acute treatment of migraine according to local product label, independent of and prior to study participation * Participants willing and able to comply with the requirements of the study. * Participants with access to an electronic device (mobile phone, tablet, laptop, etc.) with internet access. Exclusion Criteria: * Participants previously exposed to a ubrogepant or rimegepant as routine therapy or through a clinical trial. * Participants with history of known contraindications to ubrogepant as per local labeling. * Participants Pregnant or planning to be pregnant or of childbearing potential not using contraception * Participants enrolled in any interventional studies that may include investigational compounds for migraine or non-AbbVie observational studies. * History or current evidence of any condition that might interfere with their ability to comply with the study requirements, in the opinion of the investigator.